Streamlining mavacamten treatment pathways: clinical and economic evaluation of point-of-care CYP2C19 genotyping
Anisha Patel1, Jessica Gadsby1, Harshil Dhutia2
1Department of Pharmacy, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, United Kingdom.
Objectives:
To evaluate whether point-of-care (POC) CYP2C19 genotyping streamlines mavacamten initiation.
Methods:
Pre-post service evaluation in a tertiary cardiology service; 10 consecutive patients underwent parallel laboratory and POC genotyping. Outcomes were concordance, turnaround time, number of appointments, patient preference, and costs.
Key Findings:
Concordance was 100%. Laboratory turnaround was 10 days; POC run time 63 min. Appointments fell from three to one. Costs decreased by £245.76 per patient for the health service and £118 for patients; break-even was about 3-4 patients per year.
Conclusions:
POC genotyping is feasible, improves efficiency and experience, and offers a credible economic case.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Metabolism: Overview
Therapeutic Drug Monitoring: Overview and Classification
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Therapeutic Drug Monitoring: Drug Analysis Methods

